Takeda, Japan’s largest pharmaceutical company, has announced plans to buy Swiss rival Nycomed for $13.6 billion (SFr12 billion).
This content was published on
1 minute
swissinfo.ch and agencies
Nycomed, which has its headquarters in Zurich, is a privately-owned company that produces a variety of prescription as well as over the counter products.
“Nycomed gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales,” said Takeda CEO Yasuchika Hasegawa in a statement on Thursday.
Takeda is known for Actos, its diabetes drug. Nycomed’s lung drug roflumilast – known as Daxas in Europe and Daliresp in the United States – is used to treat chronic obstructive pulmonary disease.
The deal would not include Nycomed’s US dermatology unit.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Synthes considers US takeover
This content was published on
Synthes said it was talking with the group about “a potential business combination transaction” but gave no financial details. It does not intend to make any further public statements unless and until a definitive agreement is reached or talks are called off. Synthes makes surgical instruments, implants and materials for repairing bone and soft tissue.…
This content was published on
Shire, which makes drugs for hyperactivity, gastrointestinal problems and rare diseases, recently established a European hub in Eysins in western Switzerland from where it aims to expand its activities outside the United States. “This is just a temporary building,” Ross Murdoch, Shire’s vice president, told swissinfo.ch. “By the middle of next year we plan to…
This content was published on
Swiss giants Novartis and Roche reported relatively healthy balance sheets for 2010, but have warned of tough times ahead. The global recession has forced the United States, Japan and European states to demand more for less from drugs firms. Roche estimates that the European and US healthcare measures will cost the group a combined SFr1…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.